Concepedia

Author

Guelten Oskay-Oezcelik

Charité - Universitätsmedizin Berlin

Also Known As

Dominique Koensgen, Guelten Oskay-Oezcelik

12

Publications

455

Citations

8

H-Index

16

Concepts

All Affiliations

Charité - Universitätsmedizin BerlinUniversity Medical Center Hamburg-EppendorfLudwig-Maximilians-Universität MünchenUniversität HamburgUniversität Greifswald
GO

About

Guelten Oskay-Oezcelik is an author at Charité - Universitätsmedizin Berlin specializing in oncology, cancer therapeutics, and ovarian cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

175

2

Obstetrics

4

4

175

3

Neurology

1

1

40

4

Pathology

1

1

16

5

Pharmacology

1

1

108

Guelten Oskay-Oezcelik

×

8

Publications

440

Citations

8

H-Index

YearCitations

Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Jalid Sehouli, Dirk Stengel, Guelten Oskay-Oezcelik,

Journal of Clinical Oncology

2008

136

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Radoslav Chekerov, Felix Hilpert, Sven� Mahner,

The Lancet Oncology

2018

108

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Jalid Sehouli, Dirk Stengel, Philipp Harter,

Journal of Clinical Oncology

2010

103

Brain metastases from epithelial ovarian cancer: overview and optimal management.

Klaus Pietzner, Guelten Oskay-Oezcelik, K. El Khalfaoui,

PubMed

2009

40

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

Dominique Koensgen, Dirk Stengel, Antje Belau,

Cancer Chemotherapy and Pharmacology

2007

16

Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology.

Rolf Richter, Guelten Oskay-Oezcelik, Radoslav Chekerov,

PubMed

2012

13

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Guelten Oskay-Oezcelik, Dominique Koensgen, Hans-Joachim Hindenburg,

PubMed

2008

13

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

Jalid Sehouli, Oumar Camara, Sven� Mahner,

Cancer Chemotherapy and Pharmacology

2010

11

Page 1